AARS Hot Topics - July 15, 2017 Issue


The AARS online Hot Topics Newsletter is an exclusive AARS member benefit!

This is a semi-monthly compilation of peer-review literature and online updates in acne and rosacea covering industry press, new medical research and what patients and your peers are talking about in patient counseling tips.

Access Hot Topics Newsletter

You don't need to spend countless hours perusing your typical online sources when you have this! Stay informed today by becoming an AARS member and receiving the Hot Topics!


Industry News

  • Valeant Pharmaceuticals International announced that affiliates of the company have agreed to sell the Obagi Medical Products business to Haitong International Zhonghua Finance Acquisition Fund for $190 million in cash.
  • Foamix Pharmaceuticals Ltd. recently announced that its board of directors has named David Domzalski as CEO, effective immediately. Domzalski succeeds Dov Tamarkin, PhD, as CEO. Tamarkin, co-founder of Foamix, will continue to serve on the board of directors and will serve as chief scientific advisor, according to a news release.
  • Study suggests that white wine, as well as liquor, are both tied to a higher risk for rosacea. That glass of Chardonnay may affect the condition of your skin according to new research that found women with certain drinking patterns had a higher risk of developing rosacea, an inflammatory skin condition.

New Medical Research

  • A recent study demonstrates differential effects of antibiotics on the gut microbiota with doxycycline, unlike metronidazole, mediating long-term changes in the murine gut microbiota. Isotretinoin had no significant effect on the faecal microbiota.
  • Recently, a monocentric pilot study was performed on 20 patients that concluded Topical ivermectin 1% cream acts by a dual, anti-inflammatory and anti-parasitic mode of action against rosacea by killing Demodex spp. in vivo, in addition to significantly improving clinical signs and symptoms in the skin.
  • A cross sectional study that aimed to describe the medications used for treating acne/rosacea in the Medicare population and evaluate differences in costs between specialties was performed recently. It concluded that the costs of prescriptions for acne/rosacea from specialists are higher than those from primary care physicians and could be reduced by choosing generic and less expensive options.
  • The novel IHS4 is a validated tool to dynamically assess HS severity and can be used both in real-life and the clinical trials setting. It was created during a study designed specifically to develop and validate such an assessment tool for hidradenitis suppurative.
  • Findings reported from a new study analysis demonstrate that the fixed dose combination of A/BPO gel 0.3%/2.5% is efficacious and safe in patients with FST I-VI with moderate and severe inflammatory acne.
  • Analysis of data from a multicenter, randomized, double-blind, parallel group, 12-week study concludes that A/BPO 0.3%/2.5% treatment achieved success and was equally effective and safe in younger vs. older subjects and in males vs. females. These results support the use of A/BPO 0.3%/2.5% in all subjects 12 and older.
  • In a clinic based survey it was found patients with acne and post inflammatory hyperpigmentation had poorer quality-of-life scores compared to patients with only acne. Having post inflammatory hyperpigmentation with acne negatively impacted self-perceptions and social/emotional functioning, especially in groups.
  • Alcohol intake was significantly associated with an increased risk of rosacea in women in a cohort study implemented to determine the association. A total of 82,737 women were included from the Nurses' Health Study II (1991-2005).
  • Isotretinoin treatment for acne does not appear to be associated with an increased risk for depression. Moreover, the treatment of acne appears to ameliorate depressive symptoms.

Clinical Reviews

  • In an effort to create an overview of syndromic hidradenitis suppurativa a summary was derived from 134 cases collected from 82 included articles. The syndromes are discussed, focusing on etiopathogenesis, clinical presentation, and treatment.
  • Currently, no conclusions can be drawn regarding the association of Isotretinoin with depression and suicide. It seems appropriate to regularly screen all patients on ITT for depressive symptoms and suicidal ideation and promptly refer them to a mental health professional if any are found.
  • Physicians and patients may have an evidence-based discussion regarding the known risk of cutaneous surgical procedures in the setting of systemic isotretinoin therapy. For some patients and some conditions, an informed decision may lead to earlier and potentially more effective interventions.
  • Recent evidence-based guidelines for acne, including those from the American Academy of Dermatology (AAD) and the European Dermatology Forum (EDF), have agreed that retinoids have an essential role in this widespread disease.
  • In this article, the author reviews topical formulations of azelaic acid used to treat papulopustular rosacea. Emphasis is placed on differences in vehicle technology and potential clinical impact of the possibility for neurosensory cutaneous tolerability reactions.

Patient Counseling / Communication

  • It is important for dermatologists to direct patients with oily skin to oil-free moisturizers containing ingredients such as dimethicone, which is known to reduce transepidermal water loss without a greasy feel and contains both occlusive and emollient properties. Some liquid face cleansers also moisturize, which may be all that is needed in patients with oily skin. Moisturizers are a must in acne!
  • There are multiple options for treating the papules, pustules and other symptoms of rosacea, but the same can’t be said about the redness…yet. From lasers and lights to new prescription creams and calming over-the-counter skin care products, dermatologists share their favorite anti-facial redness strategies.